WAM
ESLA icon

Wolverine Asset Management’s Estrella Immunopharma ESLA Stock Holding History

Wolverine Asset Management’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487 Hold
468
– – ﹤0.01% 1607
2026
Q1 		$496 Buy
+468
New +$538 ﹤0.01% 1618

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wolverine Asset Management's ESLA Position: Q2 2026 in Review

Wolverine Asset Management held its Estrella Immunopharma (ESLA) position steady in Q2 2026 at 468 shares worth $487. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Wolverine Asset Management first reported a position in ESLA in Q1 2026 and has held it in 2 quarters since. The position peaked at $496 in Q1 2026. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Wolverine Asset Management held 468 shares of Estrella Immunopharma worth $487 as of Q2 2026.
  • Wolverine Asset Management left its Estrella Immunopharma share count unchanged in Q2 2026.
  • Estrella Immunopharma made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1607 holding.
  • Wolverine Asset Management first reported a position in Estrella Immunopharma in Q1 2026 and has held it in 2 quarters since.
  • Wolverine Asset Management's Estrella Immunopharma position peaked at $496 in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.